Suppr超能文献

被包囊和未被包囊的新型隐球菌的趋化性发生及替代补体途径的激活

Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.

作者信息

Laxalt K A, Kozel T R

出版信息

Infect Immun. 1979 Nov;26(2):435-40. doi: 10.1128/iai.26.2.435-440.1979.

Abstract

In the presence of serum, whole cells of encapsulated and non-encapsulated Cryptococcus neoformans generated a chemotactic response by neutrophils. Heat inactivation of serum ablated all chemotactic activity. Cryptococcal polysaccharide was not chemotaxigenic. Assays for alternative complement pathway activation such as depletion of alternative complement pathway factor B or electrophoretic conversion of factor B closely paralleled chemotaxis assays. Cells of encapsulated and non-encapsulated C. neoformans activated the alternative complement pathway, whereas cryptococcal polysaccharide was inactive. Failure of the capsular material to activate the alternative pathway was not due to serotype specificity because polysaccharide of several serotypes failed to achieve activation. The results suggest that chemotaxigenesis and alternative complement pathway activation are functions of the yeast cell wall. The results support our proposal that the cryptococcal capsul does not prevent potential opsonins from reaching binding and activation sites at the yeast cell wall or the release of biologically active soluble cleavage products into the surrounding medium; however, cell wall-bound cleavage products remain bound to the cell wall beneath the capsule. Therefore, they are unable to participate as opsonins in phagocytosis.

摘要

在有血清存在的情况下,被包裹和未被包裹的新型隐球菌全细胞会引发中性粒细胞的趋化反应。血清经热灭活后,所有趋化活性均消失。隐球菌多糖没有趋化作用。对替代补体途径激活的检测,如替代补体途径因子B的消耗或因子B的电泳转化,与趋化性检测密切相关。被包裹和未被包裹的新型隐球菌细胞激活了替代补体途径,而隐球菌多糖则无活性。荚膜物质未能激活替代途径并非由于血清型特异性,因为几种血清型的多糖都未能实现激活。结果表明,趋化作用和替代补体途径激活是酵母细胞壁的功能。这些结果支持了我们的提议,即隐球菌荚膜并不能阻止潜在的调理素到达酵母细胞壁上的结合和激活位点,也不能阻止生物活性可溶性裂解产物释放到周围介质中;然而,细胞壁结合的裂解产物仍结合在荚膜下方的细胞壁上。因此,它们无法作为调理素参与吞噬作用。

相似文献

3
Anti-chemotactic activity of capsular polysaccharide of Cryptococcus neoformans in vitro.
Microbiol Immunol. 1997;41(9):657-64. doi: 10.1111/j.1348-0421.1997.tb01908.x.
5
6
Role of the capsule in phagocytosis of Cryptococcus neoformans.
Rev Infect Dis. 1988 Jul-Aug;10 Suppl 2:S436-9. doi: 10.1093/cid/10.supplement_2.s436.
7
Binding of cryptococcal polysaccharide to Cryptococcus neoformans.
Infect Immun. 1984 Mar;43(3):879-86. doi: 10.1128/iai.43.3.879-886.1984.

引用本文的文献

2
The Vi capsular polysaccharide enables Salmonella enterica serovar typhi to evade microbe-guided neutrophil chemotaxis.
PLoS Pathog. 2014 Aug 7;10(8):e1004306. doi: 10.1371/journal.ppat.1004306. eCollection 2014 Aug.
3
In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.
Mol Immunol. 2011 Sep;48(15-16):2009-18. doi: 10.1016/j.molimm.2011.06.215. Epub 2011 Jul 1.
4
Cryptococcal interactions with the host immune system.
Eukaryot Cell. 2010 Jun;9(6):835-46. doi: 10.1128/EC.00039-10. Epub 2010 Apr 9.
5
The capsule of the fungal pathogen Cryptococcus neoformans.
Adv Appl Microbiol. 2009;68:133-216. doi: 10.1016/S0065-2164(09)01204-0.
6
Role of complement in protection against Cryptococcus gattii infection.
Infect Immun. 2009 Mar;77(3):1061-70. doi: 10.1128/IAI.01119-08. Epub 2008 Dec 29.
8
Modulation of C5aR expression on human neutrophils by encapsulated and acapsular Cryptococcus neoformans.
Infect Immun. 2002 Jul;70(7):3363-70. doi: 10.1128/IAI.70.7.3363-3370.2002.

本文引用的文献

2
Tissue changes and tissue diagnosis in cryptococcosis; a study of 26 cases.
Am J Clin Pathol. 1955 Jan;25(1):14-24. doi: 10.1093/ajcp/25.1.14.
4
Prognostic factors in cryptococcal meningitis. A study in 111 cases.
Ann Intern Med. 1974 Feb;80(2):176-81. doi: 10.7326/0003-4819-80-2-176.
10
Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation.
Immunochemistry. 1976 Apr;13(4):317-24. doi: 10.1016/0019-2791(76)90341-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验